Peptide Drugs for Photopharmacology: How Much of a Safety Advantage Can Be Gained By Photocontrol?
Future Drug Discovery · 2020
DOI: 10.4155/fdd-2019-0033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Drug Discovery, 2020. Verfasst von Oleg Babii und 10 weiteren Autor:innen. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Babii, O., Afonin, S., Schober, T., Garmanchuk, L. V., Ostapchenko, L. I., Yurchenko, V., Zozulya, S., Tarasov, O., Pishel, I., Ulrich, A. S., & Komarov, I. V. (2020). Peptide Drugs for Photopharmacology: How Much of a Safety Advantage Can Be Gained By Photocontrol?. Future Drug Discovery. https://doi.org/10.4155/fdd-2019-0033
Vancouver
Babii O, Afonin S, Schober T, Garmanchuk LV, Ostapchenko LI, Yurchenko V, et al. Peptide Drugs for Photopharmacology: How Much of a Safety Advantage Can Be Gained By Photocontrol?. Future Drug Discovery. 2020. doi:10.4155/fdd-2019-0033
BibTeX
@article{Babii2020,
author = {Babii, Oleg and Afonin, Sergii and Schober, Tim and Garmanchuk, Liudmyla V and Ostapchenko, Liudmyla I and Yurchenko, Volodymyr and Zozulya, Sergey and Tarasov, Oleksandr and Pishel, Iryna and Ulrich, Anne S and Komarov, Igor V},
title = {Peptide Drugs for Photopharmacology: How Much of a Safety Advantage Can Be Gained By Photocontrol?},
journal = {Future Drug Discovery},
year = {2020},
doi = {10.4155/fdd-2019-0033}
}
EUVIMED